AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

6.7M

Current Price

$0.11
-0.0057 (-4.8469%)

Book Price

$-0.24
Overvalued by 316.99%
Financial Institution

Company Metrics

  • 2.25 P/E
  • 131.22 P/S
  • 1.07 P/B
  • 0.082 EPS
  • 0.05 / 0% Dividend
  • 111,811.00 Avg. Vol.
  • 37.45M Shares
  • 6.7M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax, Inc. (AFFY): Affymax: Putting The Pieces Together [Amgen, Inc ...
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS┬« (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
After reviewing the summary adverse event report data highlighting a shocking number of deaths associated with Omontys, (discussed here), we followed-up with the FDA to request more information.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Affymax, Inc. (AFFY): Don't Believe In Affymax - The Stock Is Probably Worthless
Seeking Alpha - Aug 29, 2013
Investors in Affymax (OTCPK:AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the ...
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Telestone Technologies Corp.
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Affymax, Inc. (AFFY): Just Like Omontys.com, Affymax Is Likely To Disappear
Seeking Alpha - Sep 10, 2013
Past case studies can provide important information about how current events are likely to play out. Regarding Affymax (OTCPK:AFFY), we conducted in depth research looking for past examples of drugs that had been subject to recalls and subsequently ...